CLINICAL ARTICLE

Gynecology

The effect of BNT162b2 SARS-CoV-2 mRNA vaccine on menstrual cycle symptoms in healthy women

Naama Lessans | Amihai Rottenstreich | Shira Stern | Adi Gilan | Tal D. Saar |
Shay Porat | Uri P. Dior

Abstract

Objective: To investigate the impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA BNT162b2 vaccine on women's menstrual cycle.

Methods: In this questionnaire-based cross-sectional study, we assessed menstrual pattern and changes in women who completed the SARS-CoV-2 mRNA BNT162b2 vaccine 3 months before and after receiving the vaccine. Included were women aged 18–50 years without known gynecologic comorbidities who regularly monitor their menstruation through electronic calendars. All participants completed a detailed questionnaire on their menstrual symptoms including information on any irregular bleeding. To minimize bias, each woman served as a self-control before and after vaccination. Primary outcome was rate of irregular bleeding following vaccination and secondary outcome was presence of any menstrual change, including irregular bleeding, mood changes, or dysmenorrhea following the vaccine.

Results: A total of 219 women met the inclusion criteria. Of them, 51 (23.3%) experienced irregular bleeding following the vaccine. Almost 40% (n = 83) of study participants reported any menstrual change following vaccination. Parity was positively associated with irregular bleeding with 26 (50%) of those suffering from irregular bleeding being multiparous compared with only 53 (31.5%) of women with no irregular bleeding (nulliparous 46% vs 60%, multiparous 50% vs 31%, rest 4% vs 8%, P = 0.049). The presence of medical comorbidities was also significantly higher among patients who experienced irregular bleeding (20.0% vs 6.0%, P = 0.003).

Conclusion: Our study shows relatively high rates of irregular bleeding and menstrual changes after receiving the SARS-CoV-2 mRNA BNT162b2 vaccine. Further research is needed to confirm our findings and to better characterize the magnitude of change and any possible long-term implications.

KEYWORDS
any menstrual change, BNT162b2 SARS-CoV-2 mRNA vaccination, irregular bleeding

Naama Lessans and Amihai Rottenstreich contributed equally to this work.

© 2022 International Federation of Gynecology and Obstetrics.
1 | INTRODUCTION

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, was declared a pandemic by the World Health Organization in 2020. In an effort to minimize morbidity and mortality, vaccines based on different platforms were rapidly developed. Among them, were two novel mRNA-based vaccines: smRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) who received Emergency Use Authorization from the US Food and Drug Administration in December 2020.

Great efforts are currently ongoing to characterize the safety and adverse effect profile of these recently approved COVID-19 vaccines. Reported adverse effects of the BNT16b2 mRNA vaccine include fatigue, headache, muscle pain, joint pain, chills, tachycardia, fever, gastrointestinal discomfort, vomiting, and myocarditis. Shortly after mass vaccination began, public concerns were raised on possible menstrual cycle changes. Reported changes included changes in bleeding pattern, menstrual period length alteration, intermenstrual spotting, and menorrhagia. In response, health authorities called for more research on the effect of the COVID-19 vaccine on menstrual cycle changes.

Israel was among the first countries to initiate a mass vaccination campaign using the BNT162b2 mRNA vaccine, with the vast majority of the adult population receiving two doses of the vaccine. Shortly after the initiation of the vaccination campaign, claims about possible changes in the menstrual cycle have arisen among Israeli women leading to concerns and anxiety regarding vaccine safety and possible implications for fertility. Hence, we aimed to investigate the possible impact of the BNT162b2 mRNA SARS-CoV-2 vaccine on women’s menstrual cycle.

2 | MATERIALS AND METHODS

We conducted a survey-based cross-sectional study. The study was carried out at a tertiary medical center between July 2021 and October 2021. Inclusion criteria were women aged 18–50 years who completed the two-dose series of the SARS-CoV-2 BNT162b2 mRNA vaccine. We excluded women who had previously contracted COVID-19, were pregnant or lactating during the study period, or had background hematologic or gynecologic diseases. Women were asked to retrospectively report their menstrual pattern and symptoms during the 3-month period before the first vaccine dose administration and during the 3-month period after the second vaccine dose administration. To minimize bias, each woman served as a self-control, and each woman’s bleeding pattern and symptoms were compared between the three cycles she reported before being vaccinated and the three cycles reported after being vaccinated.

All women completed a questionnaire including: (1) demographic data; (2) medical and gynecologic background; and (3) menstrual symptoms including: duration of menses, frequency, regularity, and volume, as well as premenstrual symptoms. We included only women who regularly follow their periods with an electronic diary, menstrual cycle tracking Apps, or any other written documentation.

The primary outcome was the rate of irregular bleeding following vaccination, defined as early or delayed menstruation of 7 days or more than the expected time of menstruation. Secondary outcome was the presence of any menstrual change, defined as one of the following: irregular bleeding (as aforementioned defined in the primary outcome), mood change during the bleeding following vaccination, or dysmenorrhea after vaccination.

2.1 | Statistical analysis

Statistical analysis was performed using IBM SPSS Statistics (version 25, IBM Corporation). Patient demographics and characteristics, as well as menstrual characteristics were reported by means ± standard deviation or percentage, as appropriate. We further compared rates of irregular bleeding and any menstrual change according to baseline characteristics, using unpaired Student t test and χ² test, as appropriate. A P value of less than 0.05 was considered statistically significant for all analyses.

2.2 | Ethics statement

Approval was obtained from the institutional review board of our medical center before recruitment (0490-21-HMO; July 7, 2021). Informed consent was given by all participants.

3 | RESULTS

We recruited 241 women to this study. Of them, 5 (2.2%) were excluded because of incomplete response and 17 (7.7%) were excluded because of background disease (polycystic ovarian syndrome, n = 11; uterine fibroids, n = 4; endometriosis, n = 1; and hematologic disease, n = 1). Two hundred and nineteen women met the inclusion criteria. Baseline characteristics of women are shown in Table 1. Mean age was 29.6 ± 8.6 years and mean parity was 1.1 ± 1.5. All participants completed the two-dose series of the BNT161b2 mRNA vaccine with a mean interval of 22.1 ± 5.1 days between doses.

Distribution of baseline menstrual characteristics is shown in Table 2. The average menstrual cycle length before the vaccine was 29.4 ± 7.6 days with duration of menses of 5.0 ± 1.3 days.

Of the 219 women who participated in the study, 51 (23.3%) experienced irregular bleeding following the vaccine. Of them, 20 (39.2%) and 31 (60.8%) reported irregular bleeding after the first and second doses of the SARS-CoV-2 BNT162b2 mRNA vaccine, respectively. Of the 51 women who experienced irregular bleeding, 34 (66.7%) reported irregular bleeding that preceded their estimated menstrual date (mean 9.9 ± 3.0 days) and 17 (33.3%) reported a delay in their expected menstrual date (mean 12.3 ± 6.3 days). Irregular bleeding was reported as light in its severity in 24 (47%), moderate
In the current study assessing the effect of the SARS-CoV-2 mRNA BNT162b2 vaccine on menstrual changes, almost 40% \( (n = 83) \) of women experienced menstrual changes and almost one-fifth reported irregular bleeding following vaccination. Higher parity and the presence of medical comorbidities were associated with the occurrence of irregular bleeding following vaccination.

Few recent studies have examined the influence of COVID-19 vaccines on the menstrual cycle. In a large survey web-based...
Any menstrual change associated with SARS-CoV-2 mRNA BNT162b2 vaccine was reported also in another retrospective study. A study from the UK, specifically assessing women with regular periods before the vaccine, has reported a 20% rate of menstrual changes, up to 4 months after receiving the first dose of the vaccine. Of note, these studies suggest that menstrual changes are not specific to a particular COVID-19 vaccine.

The effect of the vaccine on the menstrual cycle may be explained by several mechanisms. Inflammatory and immunologic mediators, secreted by endometrial cells, play key roles in endometrial breakdown, regeneration, and repair. The vaccine's mechanism of action involves modulation of the immunologic milieu and this may provide a possible explanation for the association between vaccination and menstrual changes. Previous studies showing the effect of certain vaccines on the immunologic and hormonal environment, may lend support to this hypothesis. Of note, the association between irregular bleeding following vaccination and the presence of comorbid conditions is not surprising, given the large body of literature reporting menstrual changes in those with non-gynecologic comorbidities.

Concerns were raised about the possible influence of the SARS-CoV-2 mRNA BNT162b2 vaccine on women's fertility. These concerns were refuted with the publication of a number of articles as well as an official statement from The American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine stating clearly that the vaccine has no negative effect on female fertility. Therefore, even if the vaccine is associated with temporary menstrual changes, it is extremely unlikely that this has any effect on current or future fertility. This is further supported by the current study finding that among those who experienced irregular bleeding following vaccination, the occurrence of any abnormal symptom was mostly transient and resolved during the study period.

Importantly, significant menstrual changes are reported also after SARS-CoV-2 infection. In a prospective study of 127 women, Khan et al. reported irregular menstruation, increase

| TABLE 3 Comparison of baseline characteristics between women with or without irregular bleeding and any menstrual change following the vaccine |
|-----------------------------------------------|
|                                            | Irregular bleeding | Any menstrual change* |
|                                            | Yes (N = 51)       | No (N = 168)          | P value | Yes (N = 83)       | No (N = 136)          | P value |
| Age (years)                                | 31.1 ± 8.1         | 30.2 ± 7.2            | 0.44    | 31.1 ± 8.3         | 30.0 ± 6.7            | 0.29    |
| Parity                                     |                    |                       |         |                    |                       |         |
| 0                                          | 46.0%              | 60.1%                 | 0.0497  | 53.7%              | 58.8%                 | 0.28    |
| 1                                          | 4.0%               | 8.3%                  | 0.0497  | 4.9%               | 8.8%                  | 0.28    |
| ≥2                                         | 50.0%              | 31.5%                 | 0.0497  | 41.5%              | 32.4%                 | 0.28    |
| Presence of background disease             | 20.0%              | 6.0%                  | 0.003   | 13.6%              | 6.6%                  | 0.09    |
| Regular medications                        | 34.3%              | 32.3%                 | 0.82    | 22.9%              | 59.0%                 | <0.001  |
| Hormonal treatment                         | 22.0%              | 29.8%                 | 0.28    | 22.0%              | 31.6%                 | 0.12    |
| Menstrual cycle length (days)              | 28.8 ± 5.8         | 29.5 ± 8.1            | 0.59    | 29.2 ± 4.9         | 29.4 ± 8.8            | 0.85    |
| Days of bleeding                           | 5.0 ± 1.3          | 5.1 ± 1.3             | 0.74    | 4.9 ± 1.3          | 5.1 ± 1.25            | 0.59    |
| Presence of dysmenorrhea                   | 75.5%              | 83.3%                 | 0.21    | 83.1%              | 79.0%                 | 0.45    |

Note: Values are presented as mean ± standard deviation or as number (%).
*Irregular bleeding, mood disturbance, or menstrual pain.
of premenstrual symptoms, and infrequent menstruation after severe illness with SARS-CoV-2. Among 177 women who recorded their menstrual pattern Li et al.\textsuperscript{26} described that nearly 20% of patients exhibited menstrual volume decrease or cycle length alterations.

The main limitation of our study is its retrospective nature. This carries an inherent selection bias as a result of the voluntary recruitment of participants. To address this limitation, we mostly recruited patients who attended our clinic. Another limitation is a possible recall bias. In an attempt to minimize this possibility, when menstrual changes were reported, we asked the study participant to attach documentation via menstrual cycle tracking apps so we could validate the report. Another limitation is the possibility of personal interpretation of some of the questions that could not be validated by a physician. To address this, the questionnaire was validated on a group of women as well as on a group of gynecologists before recruiting commenced. Finally, the lack of a control group of women is an additional potential caveat. Our study was conducted on women who received two doses of the SARS-CoV-2 mRNA BNT162b2 vaccine. As such, our findings may not be applicable for other COVID-19 vaccines. However, similar findings were reported in two recently published studies\textsuperscript{16,26} examining the SARS-CoV-2 mRNA BNT162b2 vaccine, which further reinforces our finding of a possible effect of the vaccine on women’s menses.

In conclusion, the effectiveness and importance of the vaccine against SARS-CoV-2 to prevent severe morbidity and mortality is now unquestionable.\textsuperscript{31} In this study, assessing the association between the SARS-CoV-2 mRNA BNT162b2 vaccine and menstrual changes, we found significant rates of menstrual changes following the vaccine. Further research is needed to confirm our findings and to better characterize the magnitude of change, its underlying mechanisms, possible long-term implications and ways to attenuate any possible negative effect of the most important tool we have to fight the ongoing pandemic—the vaccine.

AUTHOR CONTRIBUTIONS

NL, AR, and UPD conceived and designed the study, analyzed and interpreted the data, and drafted the manuscript; data were acquired by NL, SS AG, and TDS. The manuscript was revised critically for important intellectual content by AR, SS, SP, UPD and the version of the manuscript to be published was approved by NL, AR, SS, AG, P, TDS, and UPD.

CONFLICT OF INTEREST

There is no conflict of interest to declare.

DATA AVAILABILITY STATEMENT

Research data are not shared.

ORCID

Naama Lessans https://orcid.org/0000-0002-3868-559X

REFERENCES

1. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157-160.
2. Mulligan MJ, Lyke KE, Kitchin N, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020;586(7830):589–93. [Internet]. 10.1038/s41586-020-2639-4
3. Ossato A, Tessari R, Trabuccci C, Zuppini T, Realdon N, Marchesini F. Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28. Eur J Hosp Pharm. 2021;21:1-6.
4. Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020;396(10249):479–88. [Internet]. 10.1016/S0140-6736(20)31605-6
5. Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study. Lancet Infect Dis 2021;21(7):939–49. [Internet]. 10.1016/S1473-3099(21)00224-3
6. Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a Nationwide setting. N Engl J Med. 2021;385(12):1078-1090.
7. Male V. Menstrual changes after covid-19 vaccination. BMJ 2021;374:n2211.
8. https://www.nytimes.com/2021/09/13/science/vaccines-menstrual-cycle-covid.html.
9. https://www.nichd.nih.gov/newsroom/news/083021-COVID-19-vaccination-menstruation.
10. https://www.rcog.org.uk/en/news/rcog-responds-to-reports-that-covid-19-vaccine-affects-periods/.
11. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397:1819-1829.
12. https://www.lancet.com/pdfs/PICTURES/Lancet_Health_2018_9_2_1096.jpg
13. Lee KMN, Junkins EJ, Fatima UA, Cox ML, Clancy KBH. Characterizing menstrual bleeding changes occurring after SARS-CoV-2 vaccination. medRxiv. 2021:1-30. doi:10.1101/2021.11.21.2126486
14. Von Woon E, Male V. Effect of COVID-19 vaccination on menstrual periods in a retrospectively recruited cohort. medRxiv. 2022:1-5. doi:10.1101/2022.03.30.22273165
15. Alvergne A, Koncourtides G, Argentieri A., et al. COVID-19 vaccination and menstrual cycle changes: a United Kingdom (UK) retrospective case-control study, 2021
16. Salomonsen LA, Hutchison JC, Gargett CE. Cyclical endometrial repair and regeneration. Development. 2021;148(17):dev199577.
17. Bettini E, Locci M. SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond. Vaccines (Basel). 2021;9(2):147. doi:10.3390/vaccines9020147
18. Suzuki S, Hosono A. No association between HPV vaccine and reported post-vaccination symptoms in Japanese young women: Results of the Nagoya study. Papillomavirus Res. 2018;5:96-103. doi:10.1016/j.pvr.2018.02.002
19. Fischinger S, Boudreau CM, Butler AL, Streeck H, Alter G. Sex differences in vaccine-induced humoral immunity. Semin Immunopathol. 2019;41(2):239-249. doi:10.1007/s00281-018-0726-5
20. Talaat KR, Halsey NA, Cox AB, et al. Rapid changes in serum cytokines and chemokines in response to inactivated influenza
vaccination. *Influenza Other Respi Viruses*. 2018;12(2):202-210. doi:10.1111/irv.12509

23. Allsworth JE, Clarke J, Peipert JF, Hebert MR, Cooper A, Boardman LA. The influence of stress on the menstrual cycle among newly incarcerated women. *Womens Health Issues*. 2007;17:202-209.

24. Steiner M, Dunn E, Born L. Hormones and mood: from menarche to menopause and beyond. *J Affect Disord*. 2003;74(1):67-83.

25. Nagma S, Kapoor G, Bharti R, et al. To evaluate the effect of perceived stress on menstrual function. *J Clin Diagn Res*. 2015;9:QC01-QC03. doi:10.7860/JCDR/2015/6906.5611

26. Li K, Chen G, Hou H, et al. Analysis of sex hormones and menstruation in COVID-19 women of child-bearing age. *Reprod Biomed Online*. 2021;42:260-267. doi:10.1016/j.rbmo.2020.09.020

27. Saei Ghare Naz M, Rostami Dovom M, Ramezani Tehrani F. The menstrual disturbances in endocrine disorders: a narrative review. *Int J Endocrinol Metab*. 2020;18(4):e106694. Published 2020 Oct 14. doi:10.5812/ijem.106694

28. Medical experts continue to assert that COVID vaccines do not impact fertility. ACOG [Internet]. Accessed 2021 May 24. https://www.acog.org/news/newsreleases/2021/02/medical-experts-assert-covid-vaccines-do-not-impact-fertility

29. https://www.asrm.org/news-and-publications/news-and-research/press-releases-and-bulletins/asrm-smfm-acog-issue-joint-statement-medical-experts-continue-to-assert-that-covid-vaccines-do-not-impact-fertility

30. Khan SM, Shilen A, Heslin KM, et al. SARS-CoV2 infection and subsequent changes in the menstrual cycle among participants in the Arizona CoVHORT study. *Am J Obstet Gynecol*. 2022;226(2):270-273. doi:10.1016/j.ajog.2021.09.016

31. Moghadas SM, Vilches TN, Zhang K, et al. The impact of vaccination on coronavirus disease 2019 (COVID-19) outbreaks in the United States. *Clin Infect Dis*. 2021;73(12):2257-2264. doi:10.1093/cid/ciab079

How to cite this article: Lessans N, Rottenstreich A, Stern S, et al. The effect of BNT162b2 SARS-CoV-2 mRNA vaccine on menstrual cycle symptoms in healthy women. *Int J Gynecol Obstet*. 2023;160:313-318. doi: 10.1002/ijgo.14356